Table 1.
Study population and clinical presentation of SARS-CoV-2 infection.
| Parameter | Athletes (n = 47) |
|---|---|
| Age, y.o. | 26 ± 4 |
| Male sex, n (%) | 32 (68) |
| Caucasian, n (%)Afro-Caribbean, n (%) | 45 (96)2 (4) |
| Years of training, y | 16 (10–20) * |
| Hours of training/week, h/week | 22 (18–26) * |
| Weight, kg | 78 ± 15 |
| Height, cm | 180 ± 11 |
| BSA, m2 | 1.9 ± 0.23 |
| BMI, kg/m2 | 24 ± 3 |
| SBP, mmHg | 112 ± 11 |
| DBP, mmHg | 71 ± 9 |
| HR, bpm | 57 ± 12 |
| Symptoms, n (%) | 41 (87) |
| Ageusia, n (%) | 19 (40) |
| Anosmia, n (%) | 15 (32) |
| Fever, n (%) | 17 (36) |
| Dyspnea, n (%) | 3 (6) |
| Diarrhea, n (%) | 3 (6) |
| Chest pain, n (%) | 1 (2) |
| Faintness, n (%) | 12 (26) |
| Headache, n (%) | 20 (43) |
| Myalgia, n (%) | 13 (28) |
| Cold, n (%) | 12 (26) |
| Palpitations, n (%) | 2 (4) |
* Median (25th–75th percentiles), BMI: body mass index; BSA: body surface area; DBP: diastolic blood pressure; HR: heart rate; SBP: systolic blood pressure.